Tafasitamab (Monjuvi)
Jump to navigation
Jump to search
Mechanism of action
Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity
Preliminary data
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed